



**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS  
DATED JULY 24, 2021 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

**BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM**

(IN CASE OF A JOINT BID APPLICATION, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the RHP dated July 24, 2021 filed with the Registrar of Companies Uttarakhand at Dehradun (the "RoC") on July 25, 2021 (if I am/we are in India) or the preliminary international wrap dated July 24, 2021 together with the RHP (the "Preliminary Offering Memorandum") (if I am/we are outside India), General Information Document for Investing in Public Issues ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Offer upto my/our Bids for maximum number of Equity Shares at or above the Offer Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible person(s) to invest in the Offer in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSB or the bank account linked with the UPI ID as mentioned in the Bid Cum Application Form, as the case may be. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP (if I am/we are in India), Preliminary Offering Memorandum (if I am/we are outside India), Abridged Prospectus, the GID, the Bid Cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders, only (i) the SCSBs (for Bids other than the Bids by Anchor Investors) and (ii) the Book Running Lead Managers (the "BRLMs") and their affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP. I/we authorise the Company to make the necessary changes in this Bid Cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid Cum Application Form as the application form for the purpose of this Offer. I/we confirm that I/we have read the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India). The investment decision cannot be based solely on the RHP/ Preliminary Offering Memorandum and should be based on independent verification and external advice.

**I/WE CONFIRM THAT:** I/We and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares confirm that I am/we are, or at any time the Equity Shares are purchased will be, the beneficial owner of such Equity Shares. I/We and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares confirm that (A) I/we have received a copy of the Preliminary Offering Memorandum and that my/our investment decision is based solely on the Preliminary Offering Memorandum; (B) I/we understand that the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction and hereby represent and warrant that my/our Bid is in compliance with the laws applicable to me/us and that the sale and delivery of any Equity Shares will be in compliance with all applicable laws; and (C) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate. I/We and any person we represent or the accounts on whose behalf we are purchasing the Equity Shares confirm that I/we (A) am/are either (i) in the United States and a "qualified institutional buyer" (as defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act") ("Rule 144A"), and am/are purchasing the Equity Shares in transactions exempt from, or not subject to, the registration requirements of the Securities Act, and have read and agree to the representations, warranties and agreements contained in the section "Transfer Restrictions" of the Preliminary Offering Memorandum, or (ii) outside the United States within the meaning of Regulation S under the Securities Act and am/are purchasing the Equity Shares in an "offshore transaction" as defined in Regulation S and pursuant to the applicable laws of the jurisdictions where those offers and sales are made, and have read and agree to the representations, warranties and agreements contained in the sections "Transfer Restrictions" and "Distribution and Solicitation Restrictions" of the Preliminary Offering Memorandum; (B) understand that the Equity Shares are being offered in a transaction not involving any public offering in the United States; and (C) understand that the Equity Shares have not been and will not be registered under the Securities Act and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws.

**FOR QIB BIDDERS:** I/we confirm that the Bid size/maximum Equity Shares applied for by me/us do not exceed the relevant regulatory approvals/limits. I am/we are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

**Further:** 1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP, I/we authorise (a) the Syndicate Member (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or the RTAs (at Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading my/our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSB as specified in the Bid Cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid Cum Application Form, as the case may be, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Bank, as the case may be, to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB/Registrar to the Offer shall reject the application. 3) I/we hereby authorise the Syndicate Member (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide my/our consent to the Stock Exchanges / Sponsor Banks / NPCI / Registrar to the Offer for collecting, storing and usage validating my/our PAN details from the bank account where my / our amount is blocked by the relevant SCSBs.

I/we acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/we are not an OCB. For further details, see "Offer Procedure" on page 307 of the RHP and "Restrictions on Foreign Ownership of Indian Securities" on page 322 of the RHP.

**INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM**

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an "indication to make an offer" during the Bid Offer period by a Bidder and not "an offer".
- The First Bidder, should mention his/her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim and any other such category of Bidders, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment of Equity Shares, delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer or RTAs/CDPs or the SCSBs nor the Company nor the Selling Shareholders shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The face value of Equity Shares is ₹ 5 each. The Price Band and minimum Bid Lot size, have been decided by the Company in consultation with the BRLMs and have been advertised in all editions of Financial Express, an English national daily newspaper, all editions of Jansatta, a Hindi national daily newspaper and the Dehradun edition of Rashtriya Sahara, a Hindi daily newspaper (Hindi being the regional language of Uttarakhand, where our Registered Office is located) at least two (2) Working Days prior to the Bid Offer Opening Date, with the relevant financial ratios calculated at the Floor Price and at the Cap Price and have been made available to the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") and together with BSE, the "Stock Exchanges") for the purpose of uploading on their websites in accordance with SEBI ICDR Regulations. In case of revision of the Price Band, the Bid Offer Period will be extended for at least three (3) additional Working Days after revision of Price Band subject to the Bid Offer Period not exceeding a total of ten (10) Working Days. In case of a force majeure, banking strike or similar circumstances, the Company and the Selling Shareholders, in consultation with the BRLMs, may for reasons to be recorded in writing extend the Bid Offer Period for minimum three (3) working days subject to the Bid Offer Period not exceeding 10 working days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the changes on the websites of the BRLMs and on the terminals of the Syndicate Members and by intimation to Designated Intermediaries and the Sponsor Bank.
- Maximum and Minimum Bid Size:** In case of Retail Individual Bidders, such number of Equity Shares in multiples of the minimum Bid Lot such that the Bid Amount does not exceed ₹ 200,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP or Preliminary Offering Memorandum.

- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** NRI Bidders bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSB to confirm or accept the UPI Mandate Request (in case of Retail Individual Bidders Bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRI Bidders Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered and Corporate Office of the Company or from the Syndicate Member or CDPs or RTAs or Registered Brokers from the Bidding centers. In accordance with applicable law and UPI Circulars, Bidders to please ensure that the SCSB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.

- Please note that application made using third party UPI ID or third party ASBA Bank A/c, are liable to be rejected.
  - QIBs and Non-Institutional Bidders cannot use UPI Mechanism to apply.
  - For Retail Individual Bidders applying using UPI.**
    - Please ensure that your Bank is offering UPI facility for Public Offers.
    - Please mention UPI ID clearly in CAPITAL LETTERS only.
    - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Retail Individual Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised?pi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised?pi=yes&intmid=43>) respectively, as updated from time to time.
    - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
    - UPI ID cannot exceed 45 characters.
    - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
    - Retail Individual Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 307 of the RHP.

- Only the First Bidder is required to sign the Bid cum Application Form / Bid Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected.
- You may be sent the RHP (if you are in India) or the Preliminary Offering Memorandum (if you are outside India) either in physical form or electronic form or both. You shall not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in or accompanies in them.
- The Equity Shares have not been and will not be registered under the Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A and referred to in the Red Herring Prospectus as "U.S. QIBs") (for the avoidance of doubt, the term "U.S. QIBs" does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Red Herring Prospectus as "QIBs") in transactions exempt from, or not subject to, the registration requirements of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S and pursuant to the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering in the United States.

**Note :** Terms used but not defined herein shall have the meaning assigned to such terms in the RHP. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLMs and the Stock Exchanges.

TEAR HERE

- In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Offer.
- In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB.
- In case of queries related to upload of Bids submitted to the relevant members of the Syndicate / RTAs / Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary.
- For UPI related queries, investors can contact NPCI at the toll free number:- 18001201740 and Mail Id:- ipo.upi@npci.org.in.

COMPANY CONTACT DETAILS	REGISTRAR TO THE OFFER CONTACT DETAILS
<b>WINDLAS BIOTECH LIMITED</b> <b>Registered Office:</b> 40/1, Mohabewala Industrial Area, Dehradun 248 110, Uttarakhand, India; Tel: +91 135 6608000 <b>Corporate Office:</b> 705-706, Vatika Professional Point, Sector-66, Golf Course Extension Road, Gurgaon 122 001, Haryana, India; Tel: +91 124 2821030; <b>Website:</b> www.windlasbiotech.com; <b>Contact Person:</b> Ananta Narayan Panda, Company Secretary and Compliance Officer; E-mail: grievance@windlasbiotech.com; <b>Corporate Identity Number:</b> U74899UR2001PLC033407	<b>LINK INTIME INDIA PRIVATE LIMITED</b> C-101, 1st Floor, 247 Park, Lal Bhadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India <b>Tel:</b> +91 22 4918 6200 <b>E-mail:</b> windlas.ipo@linkintime.co.in <b>Website:</b> www.linkintime.co.in <b>Investor Grievance ID:</b> windlas.ipo@linkintime.co.in <b>Contact Person:</b> Shanti Gopalkrishnan <b>SEBI Registration Number:</b> INR000004058

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

This is an abridged prospectus containing salient features of the Red Herring Prospectus dated July 24, 2021 (the “RHP” or “Red Herring Prospectus”). You are encouraged to read greater details available in the RHP. Unless otherwise specified all capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

**THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.**

Please ensure that you have read the RHP, this Abridged Prospectus (“Abridged Prospectus”) and the general information document for investing in public offers (“GID”) undertaken through the Book Building Process before applying in the Offer (as defined below). You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the Stock Exchanges (as defined below), Members of the Syndicate, Registered Brokers, Collecting Depository Participants (“CDPs”), Registrar to the Offer, Registrar and Share Transfer Agents (“RTAs”), Banker to the Offer, investors’ associations or Self Certified Syndicate Banks (“SCSBs”). You may also download the RHP from the websites of the Securities and Exchange Board of India (“SEBI”) at [www.sebi.gov.in](http://www.sebi.gov.in), the Stock Exchanges where the Equity Shares (as defined below) are proposed to the listed, i.e., BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) and together with BSE, the “Stock Exchanges” at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and the Book Running Lead Managers (“BRLMs”) at [www.sbicap.com](http://www.sbicap.com); [www.damcapital.in](http://www.damcapital.in) and [www.iifcap.com](http://www.iifcap.com).

**Restrictions:** This Abridged Prospectus may only be accessed by investors outside of India that have read the Preliminary Offering Memorandum of the Company dated July 24, 2021, a copy of which is available to eligible investors from the BRLMs.

# windlas

## WINDLAS BIOTECH LIMITED

Our Company was incorporated as ‘Windlas Biotech Limited’ on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by the Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana, at New Delhi (“RoC Delhi”). Our Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The registered office of our Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by our Shareholders on August 22, 2009. The alteration with respect to the place of the registered office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand at Kanpur on February 18, 2011. Subsequently, our Company was converted into a private limited company pursuant to a special resolution passed by our Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to ‘Windlas Biotech Private Limited’ was granted by the Registrar of Companies, Uttarakhand at Kanpur on July 22, 2016. Our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders on April 3, 2021, and the name of our Company was changed to ‘Windlas Biotech Limited’. A fresh certificate of incorporation dated April 15, 2021, consequent upon change of name on conversion to a public limited company was granted by the Registrar of Companies, Uttarakhand at Dehradun (“RoC”). For further details in relation to changes in the registered office and name of our Company, see “History and Certain Corporate Matters” on page 162 of the RHP.

**Registered Office:** 40/1, Mohabewala Industrial Area, Dehradun 248 110, Uttarakhand, India; **Tel:** +91 135 6608000

**Corporate Office:** 705-706, Vatika Professional Point, Sector-66, Golf Course Extension Road, Gurgaon 122 001, Haryana, India; **Tel:** +91 124 2821030

**Website:** [www.windlasbiotech.com](http://www.windlasbiotech.com); **Contact Person:** Ananta Narayan Panda, Company Secretary and Compliance Officer; **E-mail:** [grievance@windlasbiotech.com](mailto:grievance@windlasbiotech.com);

**Corporate Identity Number:** U74899UR2001PLC033407

**OUR PROMOTERS: ASHOK KUMAR WINDLASS, HITESH WINDLASS, MANOJ KUMAR WINDLASS AND AKW WBL FAMILY PRIVATE TRUST**
**OFFER DETAILS, LISTING AND PROCEDURE**

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹5 EACH (“EQUITY SHARES”) OF WINDLAS BIOTECH LIMITED (“COMPANY”) FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) AGGREGATING UP TO ₹[●] MILLION (THE “OFFER”) COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹1,650 MILLION (THE “FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 5,142,067 EQUITY SHARES, COMPRISING OF UP TO 1,136,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY VIMLA WINDLASS (THE “INDIVIDUAL SELLING SHAREHOLDER”) AND UP TO 4,006,067 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY TANO INDIA PRIVATE EQUITY FUND II (THE “INVESTOR SELLING SHAREHOLDER”, AND COLLECTIVELY WITH THE INDIVIDUAL SELLING SHAREHOLDER, THE “SELLING SHAREHOLDERS”, AND SUCH EQUITY SHARES, THE “OFFERED SHARES”) AGGREGATING UP TO ₹[●] MILLION (THE “OFFER FOR SALE). THE OFFER SHALL CONSTITUTE [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY OUR COMPANY AND THE SELLING SHAREHOLDERS IN CONSULTATION WITH THE BRLMS AND WILL BE ADVERTISED IN ALL EDITIONS OF FINANCIAL EXPRESS, AN ENGLISH NATIONAL DAILY NEWSPAPER, ALL EDITIONS OF JANSATTA, A HINDI NATIONAL DAILY NEWSPAPER AND THE DEHRADUN EDITION OF RASHTRIYA SAHARA, A HINDI DAILY NEWSPAPER (HINDI BEING THE REGIONAL LANGUAGE OF UTTARAKHAND, WHERE OUR REGISTERED OFFICE IS LOCATED) EACH WITH WIDE CIRCULATION AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE BSE LIMITED (“BSE”) AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE”, AND TOGETHER WITH BSE, THE “STOCK EXCHANGES”) FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI ICDR REGULATIONS”). DETAILS ABOUT THE BASIS OF THE OFFER PRICE WILL BE AVAILABLE ON THE WEBSITES OF THE STOCK EXCHANGES.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Selling Shareholders may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Bank.

The Equity Shares to be Allotted through the RHP are proposed to be listed on the Stock Exchanges. Our Company has received ‘in-principle’ approvals from BSE and NSE for the listing of the Equity Shares pursuant to their letters dated May 21, 2021 and June 22, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be BSE.

**PROCEDURE**

If you wish to know about processes and procedures applicable to public offer, you may request for a copy of the GID from the BRLMs or download it from the websites of the Stock Exchanges at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) or from the websites of the BRLMs at [www.sbicap.com](http://www.sbicap.com); [www.damcapital.in](http://www.damcapital.in) and [www.iifcap.com](http://www.iifcap.com).

**ELIGIBILITY FOR THE OFFER – REGULATION 6(1) OF THE SEBI ICDR REGULATION**

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements), Regulations, 2018, as amended (“SEBI ICDR Regulations”) through the Book Building Process and in compliance with Regulation 6(1) of the SEBI ICDR Regulations.

Whether the Company is compulsorily required to allot at least 75% of the net Offer to Qualified Institutional Buyers – No



**INDICATIVE TIMELINE**

<b>BID/OFFER OPENS ON</b>	August 4, 2021 <sup>(1)</sup>	<b>Initiation of refunds (if any, for Anchor Investors)/ unblocking of funds from ASBA Account*</b>	On or about August 12, 2021
<b>BID/OFFER CLOSES ON</b>	August 6, 2021 <sup>(2)</sup>	<b>Credit of Equity Shares to demat accounts of Allottees</b>	On or about August 13, 2021
<b>Finalisation of Basis of Allotment with the Designated Stock Exchange</b>	On or about August 11, 2021	<b>Commencement of trading of the Equity Shares on the Stock Exchanges</b>	On or about August 17, 2021

<sup>(1)</sup> Our Company and the Selling Shareholders, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. Anchor Investor Bid/ Offer Period shall be one Working Day prior to the Bid/ Offer Opening Date in accordance with the SEBI ICDR Regulations i.e. August 3, 2021.

<sup>(2)</sup> UPI mandate end time and date shall be at 12.00 p.m. on August 9, 2021.

\* In case of (i) any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) for cancelled/ withdrawn/ deleted ASBA Forms, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher from the date on which the request for cancellation/ withdrawal/ deletion is placed in the Stock Exchanges bidding platform until the date on which the amounts are unblocked (ii) any blocking of multiple amounts for the same ASBA Form (for amounts blocked through the UPI Mechanism), the Bidder shall be compensated at a uniform rate ₹100 per day or 15% per annum of the total cumulative blocked amount except the original application amount, whichever is higher from the date on which such multiple amounts were blocked till the date of actual unblock; (iii) any blocking of amounts more than the Bid Amount, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the difference in amount, whichever is higher from the date on which such excess amounts were blocked till the date of actual unblock; (iv) any delay in unblocking of non-allotted/ partially allotted Bids, exceeding four Working Days from the Bid/Offer Closing Date, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher for the entire duration of delay exceeding four Working Days from the Bid/ Offer Closing Date by the SCSB responsible for causing such delay in unblocking. The post Offer BRLMs shall be liable for compensating the Bidder at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher from the date of receipt of the Investor grievance until the date on which the blocked amounts are unblocked.

**GENERAL RISKS**

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 19 of the RHP and “Internal Risk Factors” on page 7 of this Abridged Prospectus.

**PRICE INFORMATION OF BRLMs**

Sr. No.	Issuer name	Listing date	Name of the merchant banker	+/- % change in closing price, [+/- % change in closing benchmark]- 30th calendar day from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90th calendar day from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180th calendar day from listing
1	G R Infraprojects Limited	July 19, 2021	SBICAP	NA	NA	NA
2	Krishna Institute of Medical Sciences Limited	June 28, 2021	IIFL	N.A.	NA	NA
3	Shyam Metalics and Energy Limited	June 24, 2021	SBICAP, IIFL	40.95% [+0.42%]	NA	NA
4	Macrotech Developers Limited	April 19, 2021	SBICAP, IIFL	30.22% [+5.21%]	75.43% [+10.89%]	NA
5	Barbeque-Nation Hospitality Limited	April 07, 2021	SBICAP, IIFL	18.77% [-0.64%]	76.97% [+6.85%]	NA
6	Nazara Technologies Ltd	March 30, 2021	IIFL	+62.57% [0.13%]	+38.22% [6.84%]	NA
7	Suryoday Small Finance Bank Ltd	March 26, 2021	SBICAP, IIFL	-18.38% [-1.14%]	-27.48% [+8.84%]	NA
8	Kalyan Jewellers India Ltd	March 26, 2021	SBICAP	-24.60% [-1.14%]	-8.33% [+8.84%]	NA
9	Laxmi Organic Industries Limited	March 25, 2021	DAM Capital	+37.85% [+0.11%]	+71.96% [+10.11%]	NA
10	Craftsman Automation Limited	March 25, 2021	IIFL	-13.82% [+0.11%]	+16.81% [+10.11%]	NA
11	Railtel Corporation of India Limited	February 26, 2021	SBICAP	35.64% [-0.15%]	37.50% [+5.32%]	NA
12	Indian Railway Finance Corporation Ltd	January 29, 2021	SBICAP, DAM Capital	-5.19% [+6.56%]	-18.65% [+9.02%]	NA
13	Mazagon Dock Shipbuilders Limited	October 12, 2020	DAM Capital	+18.90% [+5.87%]	+52.90% [+20.25%]	+45.79% [+24.34%]

**Notes:**

1. Disclosures subject to recent 7 issues (initial public offerings) in current financial year and two preceding financial years managed by each BRLMs with common issues disclosed once.
2. The 30th, 90th and 180th calendar day computation includes the listing day. If either of the 30th, 90th or 180th calendar days is a trading holiday, the previous trading day is considered for the computation. Have taken the issue price to calculate the % change in closing price as on 30th, 90th and 180th day. Have taken the closing price of the applicable benchmark index as on the listing day to calculate the % change in closing price of the benchmark as on 30th, 90th and 180th day.
3. The Nifty 50 index is considered as the Benchmark Index
4. NA - Not Applicable (Period not completed).

For further details, please refer to price information of past issues handled by BRLMs on pages 294, 295 and 296 of the RHP.

**BOOK RUNNING LEAD MANAGERS**

<b>SBI Capital Markets Limited</b> Tel: +91 22 2217 8300 E-mail: windlas.ipo@sbicaps.com Investor Grievance ID: investor.relations@sbicaps.com	<b>DAM Capital Advisors Limited</b> (Formerly IDFC Securities Limited) Tel: +91 22 4202 2500 E-mail: windlas.ipo@damcapital.in Investor Grievance ID: complaint@damcapital.in	<b>IIFL Securities Limited</b> Tel: +91 22 4646 4600 E-mail: windlas.ipo@iiflcap.com Investor Grievance ID: ig.ib@iiflcap.com
---	---	--

## IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

<b>Name of Syndicate Members</b>	SBICAP Securities Limited, Investec Capital Services (India) Private Limited and Sharekhan Limited
<b>Name of Registrar to the Offer and contact details</b>	<b>Link Intime India Private Limited</b> Tel: +91 22 4918 6200 E-mail: windlas.ipo@linkintime.co.in Investor Grievance ID: windlas.ipo@linkintime.co.in Contact Person: Shanti Gopalkrishnan
<b>Statutory Auditor of the Company</b>	S.S. Kothari Mehta & Company
<b>Name of Credit Rating Agency and IPO Grading obtained and Name of Debenture Trustees</b>	Not Applicable
<b>Self Certified Syndicate Banks</b>	The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA, where the Bid Amount will be blocked by authorising an SCSB, a list of which is available on the website of SEBI at <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmld=34">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmld=34</a> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to RIBS using the UPI Mechanism, a list of which is available on the website of SEBI at <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmld=40">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmld=40</a> or such other website as may be prescribed by SEBI and updated from time to time. Applications through UPI in the Offer can be made only through the SCSBs mobile applications (apps) whose name appears on the SEBI website. A list of SCSBs and mobile application, which, are live for applying in public issues using UPI Mechanism is provided as Annexure 'A' to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019. The list is available on the website of SEBI at <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmld=43">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&amp;intmld=43</a> and updated from time to time and at such other websites as may be prescribed by SEBI from time to time.
<b>Registered Brokers</b>	The list of the Registered Brokers eligible to accept ASBA forms, including details such as postal address, telephone number and e-mail address, is provided on the websites of the BSE and the NSE at <a href="http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?">www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?</a> And <a href="http://www.nseindia.com/products/content/equities/ipos/ipo_mem_terminal.htm">www.nseindia.com/products/content/equities/ipos/ipo_mem_terminal.htm</a> , respectively, as updated from time to time. For further details, see section "Offer Procedure" on page 307 of the RHP.
<b>Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable</b>	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address is provided on the websites of Stock Exchanges at <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?">http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?</a> and <a href="http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm">http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm</a> , respectively, as updated from time to time. The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as their name and contact details is provided on the websites of BSE at <a href="http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?">http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?</a> and on the website of NSE at <a href="http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm">http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm</a> , as updated from time to time. For further details, see "Offer Procedure" on page 307 of the RHP.

### PROMOTERS OF OUR COMPANY

Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass and AKW WBL Family Private Trust are the Promoters of our Company. As on the date of the Red Herring Prospectus, our Promoters cumulatively hold 12,781,346 Equity Shares, equivalent to 70.20% of the pre-Offer, issued, subscribed and paid-up Equity Share capital of our Company. For details of the build-up of the Promoters' shareholding in our Company, see "Capital Structure" on page 73 of the RHP.

#### Details of our Promoters:

**Ashok Kumar Windlass** is the Wholtime Director of our Company. He holds a diploma in civil engineering from Government Polytechnic, Ambala City. He has over 20 years of experience in the manufacturing and pharmaceutical business in India. He is one of our Promoters and one of the founders of our Company. He is one of the first directors of our Company and was appointed as the Managing Director of our Company on April 1, 2001 and subsequently appointed as the Wholtime Director on May 3, 2021.

**Hitesh Windlass** is the Managing Director of our Company. He holds a bachelor's degree in ceramic engineering from the Indian Institute of Technology, Banaras Hindu University, a master's degree in science in materials science and engineering from The Georgia Institute of Technology and a master's degree in business administration from the Graduate School of Business, University of Chicago. He has over 13 years of experience in the field of management.

**Manoj Kumar Windlass** is the Joint Managing Director of our Company. He holds a bachelor's degree in business administration from Georgia State University, Atlanta. He has over 15 years of experience in product development, operations, procurement and portfolio functions of the medicine business.

#### AKW WBL Family Private Trust ("Promoter Trust")

The Promoter Trust was settled pursuant to a trust deed dated April 5, 2021. The office of the Promoter Trust is located at H No. D-1/2b Hibiscus Sec 50, Near SS Plaza, Gurugram, Haryana, India 122 001.

For further details, see "Our Management" and "Our Promoters and Promoter Group" beginning on page 169 and page 187, respectively, of the RHP.

### OUR BUSINESS OVERVIEW AND STRATEGY

We are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India in terms of revenue (*Source: CRISIL Report*). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubility, we provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices ("GMP") with a focus on improved safety, efficacy and cost. In Fiscal 2020, our market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (*Source: CRISIL Report*). In addition to providing services and products in the CDMO market, we also sell our own branded products in the trade generics and OTC markets as well as export generic products to several countries.

**Our Competitive Strengths:** 1) CDMO player with focus on the chronic therapeutic category. 2) Innovative portfolio of complex generic products supported by robust R&D capabilities. 3) Efficient and quality compliant manufacturing facilities with significant entry barriers. 4) Long-term relationships with Indian pharmaceutical companies. 5) Consistent track record of financial performance. 6) Experienced Promoters and senior management with a professional and technically qualified team.

**Our strategies:** 1) Capitalize on expansion opportunities by leveraging our leadership position in the CDMO industry. 2) Continue to grow our CDMO customer base. 3) Expand our product portfolio and delivery systems by enhancing R&D and manufacturing capabilities. 4) Focus on the Domestic Trade Generics and OTC Brands SBV and high growth export markets by capitalizing on industry opportunities. 5) Foray into high growth injectables segment. 6) Selectively pursue strategic investments and acquisitions.

**BOARD OF DIRECTORS**

Sr. No.	Name	Designation	Experience including current/past position held in other firms
1.	Vivek Dhariwal	Chairman and Non-Executive Independent Director	He holds a master's degree in science from University of Kentucky. He has over 20 years of experience in manufacturing and supply operations. He was previously associated with ICI India Limited, Baxter India Private Limited and Pfizer Limited.
2.	Ashok Kumar Windlass	Wholtime Director	He has over 20 years of experience in the manufacturing and pharmaceutical business in India. He is one of our Promoters and founders of our Company. He is a director of Windlas Exports Private Limited and Ashok Vimla Trusteeship Services Private Limited.
3.	Hitesh Windlass	Managing Director	He has set up our Domestic Trade Generics, OTC Brands and Exports SBVs and plays a significant role in driving the technical operations, quality, R&D, manufacturing strategy and financial strategy of our Company. He has over 13 years of experience in the field of management. He is a director of Medicines Company (India) Private Limited and Windlas Inc.
4.	Manoj Kumar Windlass	Joint Managing Director	He has over 15 years of experience in product development, operations, procurement and portfolio functions of the medicine business. He has set up our CDMO Services and Products SBV of our Company. He is a director of Windlas Exports Private Limited.
5.	Pawan Kumar Sharma	Executive Director	He holds a bachelor's degree in Law from the Hemwati Nandan Bahuguna Garhwal University, Srinagar (Garhwal). He is responsible for commercial and administrative activities of the Company. He has over 20 years of experience in the pharmaceutical industry.
6.	Prachi Jain Windlass	Non-Executive Director	She holds a master's degree in science from University of Southern California and a master's degree in business administration from University of Chicago. She was associated with Boston Consulting Group and is associated with Michael & Susan Dell Foundation India LLP.
7.	Srinivasan Venkataraman	Non-Executive Independent Director	He is a fellow member of the ICAI. He was associated with Wealth Tree Advisors Private Limited, Hines, Aon Global Insurance Services Private Limited, and Lovelock & Lewes. He is a director of Moneytree Advisors Private Limited and Practus Business Transformation Private Limited.
8.	Gaurav Gulati	Non-Executive Independent Director	He has a master's degree in business administration from University of Chicago Booth School of Business. He was associated with Oyo Hotels and Homes Private Limited and is a director of companies including Chefed Foods Private Limited and Newgrowth Capital Advisors Private Limited.

For further details, please see "Our Management" beginning on page 169 of the RHP.

**OBJECTS OF THE OFFER**

The Offer comprises a Fresh Issue by our Company and an Offer for Sale by the Selling Shareholders. For further details of the Offer for Sale, see "The Offer" on page 54 of the RHP. Our Company proposes to utilise the Net Proceeds towards funding of the following objects:

1. Purchase of equipment required for (i) capacity expansion of our existing facility at Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant-II;
2. Funding incremental working capital requirements of our Company;
3. Repayment/prepayment of certain of our borrowings; and
4. General corporate purposes.

**Net Proceeds:** The details of the proceeds from the Fresh Issue are summarised in the following table:

Particulars	Estimated amount (₹ in million)
Gross Proceeds of the Fresh Issue	1,650.00
(Less) Offer related expenses in relation to the Fresh Issue <sup>(1)</sup>	●
<b>Net Proceeds<sup>(1)</sup></b>	<b>●</b>

<sup>(1)</sup> To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with the RoC.

**Utilisation of Net Proceeds:** The Net Proceeds are proposed to be utilised in accordance with the details provided in the following table: (₹ in million)

Particulars	Amount to be funded from the Net Proceeds	Estimated deployment of the Net Proceeds	
		Fiscal 2022	Fiscal 2023
Purchase of equipment required for (i) capacity expansion of our existing facility at our Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant – II	500.00	400	100
Funding incremental working capital requirements of our Company	475.62	294.73	180.89
Repayment/prepayment of certain of our borrowings	200.00	200.00	NIL
General corporate purposes <sup>(1)</sup>	●	●	●
<b>Total</b>	<b>●</b>	<b>●</b>	<b>●</b>

<sup>(1)</sup> To be finalized upon determination of the Offer Price and updated in the Prospectus prior to filing with the RoC. The amount utilised for general corporate purposes shall not exceed 25% of the Net Proceeds.

**Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public issues / rights issues, if any, of the Company in the preceding 10 years:** Not Applicable.

**Terms of Issuance of Convertible Security, if any:** Not Applicable.

**Name of Monitoring Agency:** HDFC Bank Limited.

**Shareholding Pattern as on the date of the RHP:**

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS**

Particulars	Pre-Offer number of shares	% holding of Pre-Offer
Promoter and Promoter Group	14,201,352	78.00%
Public	4,006,067	22.00%
Non Promoters- Non Public	-	-
Total	18,207,419	100.00%

Number of Equity Shares proposed to be sold by Selling Shareholders:

S. No.	Selling Shareholder	Number of Equity Shares offered in the Offer for Sale
A.	Individual Selling Shareholder	
	Vimla Windlass	1,136,000 Equity Shares
B.	Investor Selling Shareholder	
	Tano India Private Equity Fund II	4,006,067 Equity Shares

**RESTATED CONSOLIDATED FINANCIAL INFORMATION**

(₹ in million, except per share data and percentages)

Particulars	Financial year ended March 31, 2021	Financial year ended March 31, 2020	Financial year ended March 31, 2019
Revenue from operations	4,276.02	3,288.52	3,072.67
Profit before Tax	217.40	246.68	761.15
Profit after Tax	155.70	162.13	638.22
Equity Share Capital	64.11	64.11	64.11
Reserves and Surplus/ Other Equity	1,927.08	2,032.48	1,871.74
Net worth	1,991.22	2,096.59	1,935.85
Basic earnings per Share (₹)	8.70	8.90	38.61
Diluted earnings per Share (₹)	8.70	8.90	37.65
Return on Net Worth	18.19%	8.04%	8.97%
Net Asset Value per Share (Basic) (₹)	109.36	115.15	117.11
Net Asset Value per Share (Diluted) (₹)	109.36	115.15	114.19

**INTERNAL RISK FACTORS**

Below mentioned risks are the top 5 risk factors as per the RHP: Please also refer to the section titled "Risk Factors" on page 19 of the RHP:

1. We depend on the success of our relationships with our CDMO customers, including leading Indian pharmaceutical companies and multinational companies. Any adverse developments or inability to enter into or maintain such relationships could have an adverse effect on our business, results of operations and financial condition.
2. We are subject to strict technical specifications, quality requirements, regular inspections and audits by our CDMO customers including leading Indian pharmaceutical companies. Our failure to comply with the quality standards and technical specifications prescribed by such customers may lead to loss of business from such customers and could negatively impact our reputation, business prospects and results of operations, including cancellation of existing and future orders which may expose us to warranty claims.
3. Our operations are dependent on research and development ("R&D"), and our inability to identify and understand evolving industry trends, technological advancements, customer preferences, regulatory change and innovate new products to meet our customers' demands may adversely affect our business.
4. The continuing impact of the COVID-19 pandemic, or any future pandemic or widespread public health emergency could materially and adversely impact our business and operations and it may be significant and continue to have an adverse effect on our business, operations and our future financial performance.
5. The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could adversely affect our business in that market, results of operations and financial condition.

**SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION**
**A. Total number of outstanding litigations against the company and amount involved**

Type of Proceeding	Number of cases	Amount involved (in ₹ million)
Material civil litigation proceedings	1	Not quantifiable
Actions taken by statutory and regulatory authorities	5	42.20
Taxation proceedings	11	35.44

**B. Brief details of top 5 material outstanding litigations against the company and amount involved**

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved (in ₹ million)
1.	Our Company has received two letters dated February 22, 2021 from Sub-Registrar – Fourth, Dehradun to the Collector Stamp/ Additional District Officer (Finance and Revenue), Dehradun in relation to forwarding of two conveyance deeds executed by Windlas Healthcare in favour of our Company, upon the amalgamation of Windlas Healthcare with our Company, for examination under sections 33 and 38 of the Indian Stamp Act, 1899 for non-payment of stamp duty amounting to ₹7.92 million and ₹3.69 million for the respective conveyance deeds and recovery thereof ("Stamp Duty Letters"). The Stamp Duty Letters note that the reliance placed by the conveyance deeds upon certain statutory notifications for availing remission of stamp duty for instruments evidencing transfer of properties between a parent company and its subsidiary company is not verifiable. Further, the Stamp Duty Letters state that there is a mention of payment of stamp duty in the Scheme of Amalgamation and that Windlas Healthcare was not originally a 100.00% subsidiary of our Company. Accordingly, the Stamp Duty Letters direct the Collector Stamp/ Additional District Officer (Finance and Revenue), Dehradun to recover the stamp duty payable on the conveyance deeds and reasonable penalty thereon. Thereafter, our Company has not received any further communication in relation to the Stamp Duty Letters.	Collector Stamp/ Additional District Officer (Finance and Revenue), Dehradun	The matter is currently pending.	₹11.61

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No.	Particulars	Litigation filed by	Current Status	Amount involved (in ₹ million)
2.	Novartis AG has filed cases against a customer of the Company and our Company, before the High Court of Delhi in relation to infringement of patent no. 229051 ("Patent"). On March 27, 2019, relating to the Patent, the High Court of Delhi had passed an interim order restraining the defendants therein from using the same product/pharmaceutical composition or any other drug which has a pharmaceutical composition in any form as may amount to infringement of the Patent. In its order dated March 26, 2021, the High Court of Delhi noted our Company's submission that we will abide by the order dated March 27, 2019. Further, the High Court of Delhi appointed local commissioners to visit the premises of our Company and the customer to prepare inventory of all the infringing goods/ products, promotional and advertising material.	Novartis AG	The matter is currently pending.	Not quantifiable
3.	The issued a notice dated January 30, 2019 to our Company for contravention of certain provisions of the Essential Commodities Act, 1955 ("Act") read with the Drugs (Price Control) Order, 2013 in respect of certain products which were seized by the DCA on January 24, 2019 as the maximum retail price ("MRP") was found higher than the ceiling price fixed by government of India vide S.O. dated April 2, 2018 of the Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, National Pharmaceutical Pricing Authority ("NPPA"). Pursuant to the subsequent our Company was directed to provide certain information to the DCA in relation to the seized product. The Company pursuant to its response dated September 30, 2019, requested the DCA to dismiss the proceedings initiated against the Company. Responses dated October 23, 2019, November 12, 2019 and December 3, 2019, provided certain additional information as required under the DCA Notices. On February 26, 2020, the State of Andhra Pradesh represented by the Drugs Inspector, Rajamahendravaram (Urban) filed a complaint before the Principal Junior Civil Judge's Court, Alamuru against our Company praying that the Company is liable for punishment of the Act.	Drugs Control Administration, Government of Andhra Pradesh	The matter is currently pending.	Not quantifiable
4.	Our erstwhile subsidiary, Windlas Healthcare, received a show cause notice from Deputy Commissioner (Assessment)-I, State tax, Dehradun ("DC, State Tax") dated October 29, 2018 rejecting the IGST refund claim of ₹3.15 million in respect of services provided by Windlas Healthcare to its then subsidiary, Windlas, Inc. alleging that the services provided by Windlas Healthcare do not qualify as export of services upon failure to satisfy the condition under section 2(6)(v) of the Integrated Goods and Services Tax Act, 2017 ("IGST Act"). Further, Windlas Healthcare was served a show cause notice from DC, State Tax dated November 22, 2018 rejecting the IGST refund claim of ₹2.36 million in respect of services provided by Windlas Healthcare alleging that the place of supply of services is to be determined in accordance with section 13(3) of the IGST Act and these services do not constitute export of services in terms of section 2(6)(iii) of the IGST Act. Windlas Healthcare filed a reply to the show cause notice dated November 22, 2018 on December 3, 2018. The DC, State Tax, vide its refund rejection order dated December 7, 2018 rejected the IGST refund claims of Windlas Healthcare. Against the refund rejection order dated December 7, 2018, Windlas Healthcare filed an appeal dated March 15, 2019 before the Joint Commissioner (Appeal), Dehradun ("JC, Appeal"). The JC, Appeal, partially allowed the appeal to the extent of IGST refund claim of ₹3.15 million in respect of services provided to Windlas, Inc. and rejected the IGST refund claim of ₹2.36 million in respect of services provided by Windlas Healthcare to its clients. On November 7, 2019, Windlas Healthcare filed writ petition bearing no. 3450/2019 before the High Court against the order of the JC, Appeal dated September 30, 2019.	Deputy Commissioner (Assessment)-I, State tax, Dehradun	The matter is currently pending.	₹5.51
5.	Our erstwhile subsidiary, Windlas Healthcare, received a show cause notice from DC, State Tax dated January 7, 2020 rejecting the IGST refund claims of, (i) ₹3.48 million in respect of services provided by Windlas Healthcare to its then subsidiary, Windlas, Inc. alleging that the services provided by Windlas Healthcare do not qualify as export of services upon failure to satisfy the condition under section 2(6)(v) of the IGST Act; and (ii) ₹0.62 million in respect of services provided by Windlas Healthcare to certain clients under respective supply and service agreements, alleging the place of supply of services is to be determined in accordance with section 13(3) of the IGST Act and these services do not constitute export of services in terms of section 2(6)(iii) of the IGST Act. Windlas Healthcare filed a reply to the show cause notice on January 20, 2020 stating, inter alia, that Windlas Healthcare and Windlas, Inc. are different corporate entities and hence, the place of provision of services cannot be determined under section 13(3) of the IGST Act. The DC, State tax, in its refund sanction/ refund rejection order dated February 15, 2020 rejected the refund claim of ₹3.48 million in respect of services provided by Windlas Healthcare to its subsidiary, Windlas, Inc. and allowed the refund claim of ₹0.62 million in respect of services provided by Windlas Healthcare to its clients. Windlas Healthcare filed an appeal dated July 29, 2020 before the JC, Appeal challenging the rejection of refund claim of ₹3.48 million.	Deputy Commissioner, State Tax, Dehradun	The matter is currently pending.	₹4.10

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action: Nil.

D. Brief details of outstanding criminal proceedings against the Promoters: As of the date of the RHP, there are no outstanding criminal proceedings against the Promoters. For further details, please see "Outstanding Litigation and Material Developments" beginning on page 279 of the RHP.

## ANY OTHER IMPORTANT INFORMATION AS PER BRLMs/COMPANY - NIL

### DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by the Government of India and the rules, guidelines/regulations issued by the SEBI, established under Section 3 of the SEBI Act, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.

### DECLARATION BY THE SELLING SHAREHOLDERS

The Selling Shareholders confirm and certify that all statements, disclosures and undertakings specifically made or confirmed by them in the Red Herring Prospectus about or in relation to them, as Selling Shareholders and their portion of the Offered Shares, are true and correct. The Selling Shareholders assume no responsibility as Selling Shareholders, for any other statements, including, any of the statements made or confirmed by or relating to the Company or any other person(s) in the Red Herring Prospectus.



**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK**

**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK**

# IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

## BIDDER'S UNDERTAKING FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid Cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

## INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an 'indication to make an offer' and not 'an offer'.
- Please ensure that the Bid options provided are in the same order as that provided in the Bid Cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your Bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Retail Individual Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment does not exceed ₹ 200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, Retail Individual Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the First Bidder is required to sign the Bid Cum Application Form /Bid Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
  - QIBs and Non-Institutional Bidders cannot use UPI Mechanism to apply.
  - For Retail Individual Bidders applying using UPI.**
    - Please ensure that your Bank is offering UPI facility for Public Offers.
    - Please mention UPI ID clearly in CAPITAL LETTERS only.
    - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Retail Individual Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlid=43>) respectively, as updated from time to time.
    - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
    - UPI ID cannot exceed 45 characters.
    - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
    - Retail Individual Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 307 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Bid Revision Form, as applicable; b. Bid Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Bid Revision Forms; c. Ensure that Acknowledgement Slip for your Bid and any other applicable documents in support of the revision are attached with the Bid Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- For revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Bid Revision Form and the Bid(s) must be made only in such Bid Revision Form or copies thereof.

## OFFER STRUCTURE

Particulars	QIBs <sup>(1)</sup>	Non-Institutional Bidders	Retail Individual Bidders
Number of Equity Shares available for Allotment/ allocation <sup>(2)</sup>	Not more than [●] Equity Shares	Not less than [●] Equity Shares available for allocation or Offer less allocation to QIB Bidders and Retail Individual Bidders	Not less than [●] Equity Shares available for allocation or Offer less allocation to QIB Bidders and Non-Institutional Bidders
Percentage of Offer size available for Allotment/ allocation	Not more than 50% of the Offer shall be available for allocation to QIBs. However, 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining balance QIB Portion (excluding the Anchor Investor Portion). The unsubscribed portion in the Mutual Fund Portion will be available for allocation to other QIBs	Not less than 15% of the Offer or the Offer less allocation to QIBs and Retail Individual Bidders will be available for allocation	Not less than 35% of the Offer or Offer less allocation to QIBs and Non-Institutional Bidders will be available for allocation
Basis of Allotment/ allocation if respective category is oversubscribed*	Proportionate as follows (excluding the Anchor Investor Portion): (a) up to [●] Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; and (b) [●] Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. Up to 60% of the QIB Portion (of up to [●] Equity Shares) may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price	Proportionate	Allotment to each Retail Individual Bidder shall not be less than the maximum Bid lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares if any, shall be allotted on a proportionate basis. For details see, "Offer Procedure" on page 307 of the RHP.
Minimum Bid	Such number of Equity Shares and in multiples of [●] Equity Shares so that the Bid Amount exceeds ₹200,000	Such number of Equity Shares and in multiples of [●] Equity Shares so that the Bid Amount exceeds ₹200,000	[●] Equity Shares
Maximum Bid	Such number of Equity Shares in multiples of [●] Equity Shares so that the Bid does not exceed the size of the Offer, subject to applicable limits	Such number of Equity Shares in multiples of [●] Equity Shares so that the Bid does not exceed the size of the Offer (excluding the QIB Portion), subject to applicable limits	Such number of Equity Shares in multiples of [●] Equity Shares so that the Bid Amount does not exceed ₹200,000
Mode of Allotment	Compulsorily in dematerialised form		
Bid Lot	[●] Equity Shares and in multiples of [●] Equity Shares thereafter		
Allotment Lot	A minimum of [●] Equity Shares and thereafter in multiples of one Equity Share		
Trading Lot	One Equity Share		
Who can apply <sup>(3)</sup>	Public financial institutions as specified in Section 2(72) of the Companies Act 2013, scheduled commercial banks, mutual funds registered with SEBI, FPIs (other than individuals, corporate bodies and family offices), VCFs, AIFs, FVCI, state industrial development corporation, insurance company registered with IRDAI, provident fund with minimum corpus of ₹250 million, pension fund with minimum corpus of ₹250 million National Investment Fund set up by the Government, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically Important NBFCs.	Resident Indian individuals, Eligible NRIs on a non-repatriable basis, HUFs (in the name of Karta), companies, corporate bodies, scientific institutions, societies, trusts and FPIs who are individuals, corporate bodies and family offices	Resident Indian individuals, Eligible NRIs and HUFs (in the name of Karta)
Terms of Payment	<b>In case of Anchor Investors:</b> Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids <sup>(4)</sup> <b>In case of all other Bidders:</b> Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder or by the Sponsor Bank through the UPI Mechanism (for Retail Individual Bidders) that is specified in the ASBA Form at the time of submission of the ASBA Form		
Mode of Bidding	Only through the ASBA process (except for Anchor Investors).		

\* Assuming full subscription in the Offer

- Our Company and the Selling Shareholders, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price Anchor Investor Allocation Price. In the event of under-subscription or non-allotment in the Anchor Investor Portion, the balance Equity Shares in the Anchor Investor Portion shall be added to the Net QIB Portion. For details, see "Offer Structure" on page 304 of the RHP.
- Subject to valid Bids being received at or above the Offer Price. This is an Offer in terms of Rule 19(2)(b) of the SCRR in compliance with Regulation 6(1) of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers. Such number of Equity Shares representing 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only. The remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received from them at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Subject to valid Bids being received at or above the Offer Price, under-subscription, if any, in the Non-Institutional Portion or the Retail Portion would be allowed to be met with spill-over from other categories or a combination of categories at the discretion of our Company and the Selling Shareholders in consultation with the BRLMs and the Designated Stock Exchange, on a proportionate basis. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories. In the event of under-subscription in the Offer, the Allotment for the valid Bids will be made, in the first instance, towards subscription for 90% of the Fresh Issue. If there remain any balance valid Bids in the Offer, the Allotment for the balance valid Bids will be made pro rata towards Equity Shares offered by the Selling Shareholders, and thereafter, towards the balance Fresh Issue. For further details, please see "Terms of the Offer" on page 299 of the RHP.
- In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such first Bidder would be required in the Bid cum Application Form and such first Bidder would be deemed to have signed on behalf of the joint holders. Our Company reserves the right to reject, in its absolute discretion, all or any multiple Bids, except as otherwise permitted, in any or all categories.
- Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Offer Price shall be payable by the Anchor Investor Pay-In Date as indicated in the CAN.
- The Bids by FPIs with certain structures as described under "Offer Procedure - Bids by FPIs" on page 310 of the RHP and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allocated and Allotted to such successful Bidders (with same PAN) may be proportionately distributed. Bidders will be required to confirm and will be deemed to have represented to our Company, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

**COMMON BID  
REVISION FORM**

**windlas**

To,  
The Board of Directors  
WINDLAS BIOTECH LIMITED

**WINDLAS BIOTECH LIMITED - INITIAL PUBLIC OFFER - NR**  
Registered Office: 40/1, Mohabewala Industrial Area, Dehradun 248 110, Uttarakhand, India; Tel: +91 135 6608000  
Corporate Office: 705-706, Vatika Professional Point, Sector-66, Golf Course Extension Road, Gurgaon 122 001, Haryana, India;  
Contact Person: Ananta Narayan Panda, Company Secretary and Compliance Officer; Tel: +91 124 2821030;  
Website: www.windlasbiotech.com; E-mail: grievance@windlasbiotech.com; Corporate Identity Number: U74899UR2001PLC033407

**100% BOOK BUILT OFFER**  
**ISIN : INE0H5001029**  
**COMPANY LEI NO : 3358008HGGLMCS46P83**

**Bid cum  
Application  
Form No.**

FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIs,  
FPIs, FVCI and REGISTERED MULTI LATERAL AND  
BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS  
ETC. APPLYING ON A REPATRIATION BASIS

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP & CODE	<b>1. NAME &amp; CONTACT DETAILS OF SOLE / FIRST BIDDER</b> Mr. /Ms./M/s. _____ Address _____ _____ Email _____ Tel. No. (with STD code) / Mobile _____
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE	
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.	
<b>2. PAN OF SOLE / FIRST BIDDER</b> _____		
<b>3. BIDDER'S DEPOSITORY ACCOUNT DETAILS</b> <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID		

**PLEASE CHANGE MY BID**

4. FROM (AS PER LAST BID OR REVISION)										Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only)										
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)									(In Figures Only)										
	(In Figures)									Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)	
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1			
Option 1																				
(OR) Option 2																				
(OR) Option 3																				

  

5. TO (REVISED BID) (ONLY RETAIL INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")										Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only)										
Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised)									(In Figures Only)										
	(In Figures)									Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)	
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1			
Option 1																				
(OR) Option 2																				
(OR) Option 3																				

6. PAYMENT DETAILS [IN CAPITAL LETTERS]										PAYMENT OPTION : FULL PAYMENT <input checked="" type="checkbox"/>									
Additional Amount Blocked (₹ in figures) _____ (₹ in words) _____																			
ASBA Bank A/c No. _____																			
Bank Name & Branch _____																			
OR UPI ID (Maximum 45 characters) _____																			

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUES ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN ALONG WITH THE BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM GIVEN OVERLEAF.

7A. SIGNATURE OF SOLE/ FIRST BIDDER	7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)	MEMBERS OF THE SYNDICATE / SUB - SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)
Date : _____, 2021	I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer. 1) _____ 2) _____ 3) _____	

TEAR HERE

<b>WINDLAS BIOTECH LIMITED</b> <b>BID REVISION FORM -</b> <b>INITIAL PUBLIC OFFER - NR</b>	<b>Acknowledgement Slip for</b> <b>Members of the Syndicate / Sub-Syndicate</b> <b>Member / Registered Broker / SCSB /</b> <b>CDP / RTA / Agent</b>	<b>Bid cum</b> <b>Application</b> <b>Form No.</b>
DPID / CLID _____		PAN of Sole / First Bidder _____
Additional Amount Blocked (₹ in figures) _____ ASBA Bank A/c No./UPI ID _____		Stamp & Signature of SCSB Branch
Bank Name & Branch _____		
Received from Mr./Ms./M/s. _____		
Telephone / Mobile _____ Email _____		

TEAR HERE

<b>WINDLAS BIOTECH LIMITED -</b> <b>BID REVISION FORM -</b> <b>INITIAL PUBLIC OFFER - NR</b>	Option 1	Option 2	Option 3	Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Name of Sole / First Bidder _____
	No. of Equity Shares				
	Bid Price				
	Additional Amount Blocked (₹ in figures)				
ASBA Bank A/c No. /UPI ID _____ Bank Name & Branch _____					<b>Acknowledgement Slip for Bidder</b>  <b>Bid cum</b> <b>Application</b> <b>Form No.</b>
Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.					